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AbsTrACT
background hearing impairment may be a modifiable 
risk factor for dementia. however, it is unclear how 
hearing associates with pathologies relevant to dementia 
in preclinical populations.
Methods Data from 368 cognitively healthy individuals 
born during 1 week in 1946 (age range 69.2–71.9 
years), who underwent structural MrI, 18F- florbetapir 
positron emission tomography, pure tone audiometry 
and cognitive testing as part of a neuroscience substudy 
the MrC National Survey of health and Development 
were analysed. the aim of the analysis was to investigate 
whether pure tone audiometry performance predicted 
a range of cognitive and imaging outcomes relevant to 
dementia in older adults.
results there was some evidence that poorer pure 
tone audiometry performance was associated with 
lower primary auditory cortex thickness, but no evidence 
that it predicted in vivo β-amyloid deposition, white 
matter hyperintensity volume, hippocampal volume 
or Alzheimer’s disease- pattern cortical thickness. A 
negative association between pure tone audiometry and 
mini- mental state examination score was observed, but 
this was no longer evident after excluding a test item 
assessing repetition of a single phrase.
Conclusion pure tone audiometry performance 
did not predict concurrent β-amyloid deposition, 
small vessel disease or Alzheimer’s disease- pattern 
neurodegeneration, and had limited impact on cognitive 
function, in healthy adults aged approximately 70 years.
INTroduCTIoN
Hearing impairment may be a modifiable risk factor 
for Alzheimer’s disease (AD) and dementia.1–3 
However, research investigating the relationship 
between hearing and biomarkers of dementia- 
associated pathologies in preclinical populations 
has been limited. Improved understanding of this 
relationship is important to determine mechanistic 
relationships, and to evaluate hearing as a screening 
tool for dementia- associated pathologies. We inves-
tigated whether pure tone audiometry performance 
related to imaging biomarkers of β-amyloid deposi-
tion (Aβ), small vessel disease, grey matter macro-
structure and cognitive performance in a cohort of 
healthy older adults all born in the same week of 
1946.
MeThods
We included data from 368 cognitively healthy 
participants drawn from Insight-46, a substudy of 
the MRC National Survey of Health and Develop-
ment (NSHD).4 All individuals were born during 
1 week in 1946.
Positron emission tomography (PET) and MRI 
data were acquired on the same 3- Tesla PET/MRI 
scanner.4 Aβ-burden was assessed over a 10- min 
period approximately 50 min after florbetapir injec-
tion (370 MBq). A standard uptake value ratio 
(SUVR) from a grey matter cortical composite using 
a white matter reference without partial volume 
correction was calculated. Positive or negative 
Aβ-status was determined using Gaussian mixture 
modelling (SUVR cut- point=0.6104).
MRI data included volumetric T1- weighted, 
T2- weighted and FLAIR images.4 Cortical thickness 
estimation was performed using Freesurfer V.6.0.5 
A priori regions of interest were: primary audi-
tory cortex (transverse temporal gyrus); planum 
temporale; and a surface- area weighted AD- sig-
nature composed of entorhinal, inferior temporal, 
middle temporal and fusiform regions.6 Hippo-
campal volume was estimated using STEPS.7 Global 
white matter hyperintensity volume (WMHV—a 
marker of small vessel disease) was estimated using 
BaMoS.8 Total intracranial volume (TIV) was calcu-
lated using Statistical Parametric Mapping 12.
A detailed neuropsychology testing battery was 
performed4 including: the mini- mental state exam-
ination (MMSE); digit- symbol substitution; logical 
memory delayed recall; matrix reasoning; and the 
12- item face- name associative memory task.
An otological history regarding hearing aid use, 
recent ear pain/discharge, tinnitus and previous 
otological diagnoses was collected. Otoscopy was 
not performed.
Audiometric thresholds were obtained for 
each ear at 0.5, 1, 2, and 4 kHz using calibrated 
Maico- MA-25 audiometers with sound- excluding 
TDH-49 earphones in audiocups using a British 
Society of Audiology recommended testing 
protocol9 in a quiet room. A pure- tone average 
(PTA) in the better hearing ear was calculated using 
thresholds for 0.5, 1, 2 and 4 kHz.
Wilcoxon rank sum tests were used to assess 
unadjusted association between binary demographic 
Hygiene and Tropical M
edicine. Protected by copyright.
 o
n
 N
ovem
ber 11, 2019 at London School of
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-321897 on 7 November 2019. Downloaded from 
2 parker t, et al. J Neurol Neurosurg Psychiatry 2019;0:1–5. doi:10.1136/jnnp-2019-321897
Neurodegeneration
Table 1 Summary statistics for auditory testing/imaging biomarkers and unadjusted relationships between demographic and performance on pure 
tone audiometry AND associations between pure tone audiometry performance and neuropsychological testing in cognitively normal older adults
binary demographics
unadjusted association with PTA
Median (IQr) PTA P value
Sex Males: 23.5 (12.5), n=187
Females: 21.25 (12.5), n=181
0.19*
Educational attainment Non- advanced: 23.75 (15), n=169
Advanced: 21.25 (10), n=199
0.09*
Childhood socioeconomic position Non- manual: 22.55 (11.25), n=218
Manual: 21.25 (15), n=150
0.95*
Adulthood socioeconomic position Non- manual: 21.25 (11.25), n=313
Manual: 23.75 (16.25), n=55
0.17*
Tinnitus No tinnitus: 21.25 (12.5), n=288
Tinnitus: 26.25 (13.75), n=80
0.0004*
Hearing aid use Non- user: 21.25 (10), n=313
user: 38.75 (16.25), n=55
<0.0001*
APOE genotype Non-ε4 carrier: 22.5 (12.5), n=258
ε4 carrier: 21.25 (13.25), n=110
0.089*
Aβ positivity, n (%) Aβ-negative: 21.88 (12.5), n=306
Aβ-positive: 23.75 (12.5), n=62
0.25*
Continuous demographics summary statistic unadjusted association with PTA
Age, years, median (IQR) 70.6 (1.1), n=368 Rho=0.07, p=0.2†
Childhood cognition, z- score, median (IQR) 0.48 (0.84), n=368 Rho=−0.02, p=0.72†
Cognitive tests summary statistic Association with PTA
univariate Multivariate β-coefficient‡ 
(95% CI)
Logical memory delayed recall (Wechsler Memory Scale- 
Revised—out of 25), mean (SD)
11.6 (3.6), n=368 r=−0.065,
p = 0.21§
−0.009
(−0.044 to 0.026)¶
Digit- symbol substitution (Wechsler Adult Intelligence Scale- 
Revised—out of 93), mean (SD)
48.8 (10.0), n=368 r=−0.047,
p = 0.36§
−0.005
(−0.098 to 0.087)¶
12- item Face- Name (out of 96), mean (SD) 65.6 (18.2), n=364 r=0.099,
p = 0.85§
−0.01
(−0.20 to 0.18)¶
Matrix Reasoning (Wechsler Abbreviated Scale of Intelligence—
out of 32), median (IQR)
25 (4), n=368 Rho=−0.11, p=0.04§ −0.037
(−0.084 to 0.007)**
MMSE (out of 30), median (IQR) 30 (1), n=368 Rho=−0.13, p=0.013§ −0.009
(−0.019 to −0.001)**
MMSE without ‘No ifs, ands or buts’ (out of 29), median (IQR) 29 (1), n=368 Rho=−0.07, p=0.21§ −0.005
(−0.015 to 0.003)**
  “No ifs, ands or buts” repetition (out of 1), proportion who 
answered Item correctly (%)
306/368, (83.2%) p=0.0017a −0.031
(−0.056 to −0.006)††
Analyses that attained statistical significance at the 5% level are highlighted in bold.
*Wilcoxon rank sum test.
†Spearman correlation.
‡Coefficient represents increase in cognitive score per dB HL increase in PTA (covariates were: age at scan; sex; APOEε4 genotype; WMHV; educational attainment; childhood 
cognitive ability; socioeconomic position; and Aβ status).
§Pearson’s correlation.
¶Linear regression models with robust SE.
**Bootstrapping.
††Logistic regression.
Aβ, β-amyloid; AD, Alzheimer’s disease; MMSE, mini- mental- state- examination; PET, positron emission tomography; PTA, pure tone average in best hearing ear; r, Pearson’s r; 
Rho, Spearman’s Rho; WMHV, white matter hyperintensity volume.
variables and PTA. Spearman correlations were used to assess 
unadjusted associations between continuous demographic vari-
ables and PTA.
Receiver operating characteristic (ROC) curves and area under 
the curve (AUC) analyses were performed to investigate whether 
PTA predicted Aβ-status following adjustment for: age at scan; 
sex; WMHV; educational attainment4; prospective childhood 
cognition4; adult and childhood socioeconomic position.4 Addi-
tional analyses incorporating APOE genotype (binarised into ε4 
carrier and non- carriers) were also performed.
As WMHV was non- normally distributed, generalised linear 
models using the gamma distribution and log link were used to 
investigate whether PTA predicted WMHV.
Linear regression models with robust standard errors were 
used to investigate whether PTA predicted grey matter macro-
structure (dependent variables=primary auditory cortex, planum 
temporale AD- signature thickness and hippocampal volume).
Linear regression models with robust standard errors were 
used to test the hypothesis that PTA predicted cognitive testing 
performance. For cognitive tests with skewed distributions 
(MMSE and Matrix Reasoning) bootstrapping with 2000 repli-
cations was used to produce bias- corrected and accelerated 95% 
CIs.
Analyses of WMHV, grey matter macrostructure and cognition 
were adjusted for age, sex, educational attainment, childhood 
cognitive ability, socioeconomic position, APOE genotype and 
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Figure 1 Association between pure tone audiometry performance and grey matter structural metrics in cognitively normal older adults following 
multivariate linear regression with robust Se. Covariates included: age at scan; sex,; APOEε4 genotype; WMhV; educational attainment; childhood cognitive 
ability; socioeconomic position’Aβ status; and tIV (for hippocampal volume analysis only). Solid line represents line of best of fit. Dashed lines represent 
95% CIs. the crosses represent raw unadjusted data points for each individual included in the analysis. AD, Alzheimer’s disease; ptA, pure tone average in 
best hearing ear; tIV, total intracranial volume; WMhV, white matter hyperintensity volume.
Aβ-status. Additional adjustment for TIV was made in WMVH 
and hippocampal volume analyses, while analysis of grey matter 
macrostructure and cognition were additionally adjusted for 
WMHV.
Exclusions from 502 participants originally recruited included: 
failure to complete scan (n=31); PET acquisition failure (n=8); 
WMHV segmentation error (n=4); MRI movement artefact 
(n=3); mild cognitive impairment, dementia and/or a major 
neurological disorder (n=48); history of otological pathology 
(eg, Meniere’s disease, surgery/trauma resulting in hearing loss, 
intercurrent infection) (n=16); equipment unavailable (n=19); 
missing APOE genotype (n=2); missing socioeconomic position 
(n=3).
resulTs
As all individuals were born in the same week, the age range at 
scanning was narrow (69.2–71.9 years). Median PTA across the 
dataset was 22.5 dB HL (decibels in hearing level) (IQR=12.5). 
Unadjusted associations between PTA and a range of variables 
are displayed in table 1. Of note, both tinnitus and hearing aid 
use were strongly associated with higher PTA (table 1).
A total of 62 participants were Aβ-positive (16.8%). Unad-
justed analyses revealed no evidence of an association between 
Aβ and PTA (table 1). Using a base model combining age, sex, 
WMHV, educational attainment, childhood cognitive ability and 
socioeconomic position, ROC analysis provided an AUC for 
Aβ-positivity of 0.55 (95% CI 0.48 to 0.63); subsequent inclu-
sion of PTA (AUC=0.56, 95% CI 0.49 to 0.64) did not improve 
the predictive ability. Incorporating APOE genotype into the 
base model provided an AUC for Aβ-positivity of 0.70 (95% 
CI 0.62 to 0.78). Again, inclusion of PTA (AUC=0.72; 95% CI 
0.64 to 0.79) did not improve this.
There was no evidence that PTA predicted WMHV in fully 
adjusted models (exponentiated coefficient=0.96; 95% CI 0.98 
to 1.01; p=0.39, which corresponds to the proportional change 
in WMHV per dB HL increase in PTA).
There was evidence of a negative association between primary 
auditory cortex thickness and PTA (figure 1). No associations 
were observed between PTA and planum temporale thickness, 
AD- signature thickness or hippocampal volume (figure 1).
There was no evidence of a relationship between PTA and a 
range of cognitive scores following covariate adjustment, except 
for a negative association between PTA and MMSE. However, 
this was no longer evident when excluding the phrase repetition 
item ‘no ifs, ands, or buts’ (table 1).
A post- hoc analysis using high frequency thresholds only 
(4 kHz rather than a PTA) was performed and produced very 
similar results (data not shown).
dIsCussIoN
We found no evidence of an association between PTA and 
Aβ-deposition in cognitively healthy individuals aged 69.2–71.9 
Hygiene and Tropical M
edicine. Protected by copyright.
 o
n
 N
ovem
ber 11, 2019 at London School of
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-321897 on 7 November 2019. Downloaded from 
4 parker t, et al. J Neurol Neurosurg Psychiatry 2019;0:1–5. doi:10.1136/jnnp-2019-321897
Neurodegeneration
years. To our knowledge, this is the first study to investigate 
the relationship between hearing and PET- derived measures of 
Aβ, although a null relationship between cerebrospinal fluid 
biomarkers of Aβ-deposition and auditory function has been 
reported in healthy older adults with a family history of AD.10 
There was also no evidence of a relationship between PTA and 
WMHV, which to our knowledge has not been investigated previ-
ously. Taken together these results suggest impaired hearing is 
not a reliable marker of preclinical Aβ-deposition or small vessel 
disease, at least early in the eighth decade. This is supported 
by a recent systematic review and meta- analysis, which found 
evidence that hearing impairment increased the risk of cognitive 
impairment and all- cause dementia, but did not increase the risk 
for AD or vascular dementia specifically.11
Beyond Aβ and small vessel disease, another potential patho-
physiological mechanism linking hearing and dementia is neuro-
degeneration. Hearing loss has been previously shown to be 
associated with grey matter atrophy including regions typically 
affected in AD.10 12 However, in our analyses, neither hippo-
campal volume nor AD- cortical signature thickness were asso-
ciated with PTA, suggesting that hearing impairment is unlikely 
to be related to AD- pattern neurodegeneration in healthy older 
adults. In contrast we found evidence for an independent asso-
ciation between PTA and primary auditory cortex thickness, 
which has been shown previously,13 but not with consideration 
of Aβ and WMHV. Although speculative, this would be consis-
tent either with a non- AD and non- vascular related degenera-
tion of this region contributing to hearing impairment, or with 
peripheral deafferentation of the cochlear nerve due to presby-
cusis leading to atrophy in primary auditory areas, although the 
cross- sectional nature of the data limits ability to infer a causal 
direction. Furthermore, the association observed was cross- 
sectional and relatively weak statistically following adjustment 
for covariates necessitating cautious interpretation.
In terms of cognition, the only significant finding was an asso-
ciation between PTA and MMSE score, which was no longer 
evident when a test item assessing repetition of a single phrase 
(‘no ifs, ands or buts’) was excluded, suggesting that although 
hearing ability had limited impact on overall cognitive function, 
hearing loss may impact acoustically demanding tests and is an 
important consideration while administering and interpreting 
such tests.
Limitations include: its cross- sectional nature; missing data; 
lack of a more detailed otological examination; and inability to 
precisely define causes of hearing loss. Future work of impor-
tance will include inclusion of longitudinal auditory, cognitive 
and neuroimaging data, and long- term follow- up. It is possible 
that auditory dysfunction does precede the development of 
cognitive impairment in AD, but that this occurs sometime after 
Aβ-deposition; individuals in this study are aged 69.2–71.9 
years and may be many years away from developing cognitive 
impairment, and the downstream pathological changes associ-
ated with hearing impairment. Neuroimaging techniques that 
assess other pathological process relevant to dementia such as 
tau- PET,14 may provide further insights. Including a broader 
range of auditory testing, specifically including tests that 
focus on central auditory processing,15 which is known to be 
impaired in established AD will also be of considerable interest. 
The majority of participants investigated had normal hearing 
thresholds, which may limit the power to detect relationships 
between hearing function and outcomes relevant to dementia. 
However, the statistically significant relationships observed 
between tinnitus, hearing aid use and primary auditory cortex 
thickness would support the notion that this study is sufficiently 
powered to detect meaningful relationships between hearing 
function and outcomes of interest.
In summary, we demonstrate that pure tone audiometry 
performance did not predict concurrent Aβ-deposition, small 
vessel disease or AD- pattern neurodegeneration, and had limited 
impact on cognitive function, in healthy adults aged approxi-
mately 70 years.
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